AI brief of an SEC Form 8-K · EUDA Health Holdings Ltd (EUDA)

EUDA issues 1.6 million shares to investors after accelerating prepaid forward deals

Negative Impact 4 of 5 financing Written later

EUDA amended its prepaid forward agreements with institutional investors on June 8, 2023, accelerating the maturity date. As a result, 1.6 million ordinary shares became immediately due to the sellers, and the sellers became entitled to retain the remaining prepayment from the trust account and the remaining shares. The share issuance adds to the existing share count and could dilute current shareholders, and the filing also reports a board change and a revised settlement with CEO Dr. Kelvin Chen.

Key points

  • 1.6 million ordinary shares issuable as Maturity Consideration, 800,000 to each of two sellers, HB Strategies LLC and Alto Opportunity Master Fund, SPC
  • Maturity Date accelerated to June 8, 2023; the sellers may retain the remaining prepayment from EUDA's trust account and remaining shares
  • Sellers received registration rights and may not sell more than 15% of the daily trading volume on any exchange business day
  • Alfred Lim was appointed Executive Director on June 6, 2023 and resigned from three board committee roles

The filing

CompanyEUDA Health Holdings Ltd (EUDA)
Form8-K, current report
Filed with the SECJun 9, 2023, 5:29 PM ET
Accession number0001493152-23-020785

Items reported: 1.01 Material Definitive Agreement1.02 Termination of Material Agreement3.02 Unregistered Equity Sale5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 09, 2023.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.